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ABSTRACT 
 
The fate of cellular mRNAs was analyzed in several cell lines of lymphoid origin, after induction 
of apoptosis by different mechanisms. Cytoplasmic mRNAs are specifically degraded as part of 
the early apoptotic response. This degradation is not species restricted and is independent of the 
cell line, the apoptotic stimulus, the intrinsic half-life of the mRNAs, and the transcriptional 
status of the gene (constitutive or inducible). mRNA degradation precedes DNA fragmentation 
and correlates with the appearance of phosphatidylserine in the outer cell membrane. In addition, 
apoptosis-induced mRNA degradation is an active process that can be dissected from other 
apoptotic hallmarks (degradation of annexin V, DNA, and poly(ADP-ribose) polymerase 
[PARP]), which suggests that apoptosis-induced mRNA degradation is controlled by a distinct 
signaling pathway. Furthermore, mRNA degradation also occurs in vivo, specifically during 
thymocyte apoptosis. Taken together, these data support the notion that degradation of mRNA is 
a general early apoptotic event that may become a new apoptotic hallmark. 
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he genetically programmed cell death process known as apoptosis is fundamental for the 
normal development and homeostasis of tissues and organs in multicellular organisms. 
The relevance of apoptosis is demonstrated both by the evolutionary conservation of basic 
steps in the corresponding pathways (1) and by the causal implication of aberrant 
apoptotic mechanisms in diseases including neurodegenerative diseases, ischemic damage, 
autoimmune disorders, and several forms of cancer (2-6). Apoptosis was originally characterized 
by morphological features such as membrane blebbing, cell shrinkage, formation of apoptotic 
bodies, chromatin condensation, nucleolus loss, and chromatin fragmentation into single or 
multiple nucleosomes (7, 8). In recent years, many molecules participating in the pathways 
mediating apoptosis have been identified (9). Caspase activation is a feature common to most of 
these pathways and leads to proteolytic cleavage of specific cell substrates (10-12), including 
poly(ADP-ribose) polymerase (PARP), lamins, histone H1 (13), and DNA protein kinase (14, 
15), as well as proteins involved in cell growth, survival, and death (11). Caspases also cleave 
the inhibitor of caspase-dependent DNase (ICAD), thus releasing active caspase-dependent 
DNase (CAD), which after translocation to the nucleus fragments chromatin (16). In addition, 
several reports have analyzed the fate of RNA during apoptosis. Indeed, [3H]uridine pulse-chase 
experiments detected a twofold increase in RNA degradation rates in rat thymocytes after 
glucocorticoid treatment (17). More recently, cleavage of both 28S ribosomal RNA (rRNA) and 
Ro ribonucleoprotein-associated Y RNAs during apoptosis was shown (18, 19), but nothing is 
known regarding the fate of cytoplasmic mRNAs. 
 
In the immune system, apoptosis plays a key role both in the control of lymphocyte maturation 
and in the maintenance of homeostasis of mature cell populations. During maturation, 
thymocytes undergo positive and negative selection, so that only about 5% successfully 
complete maturation and leave the thymus, and the large majority of immature cells die by 
apoptosis (20, 21). In addition, during an immune response, mature T cells of the appropriate 
antigenic specificity undergo clonal expansion and acquire effector functions, leading to antigen 
elimination. After antigen removal, the majority of expanded T cells must be eliminated to 
maintain homeostasis, while a small fraction of the T cell population remains as long-lasting 
memory cells. Apoptosis induced either by death receptor triggering or by growth factor 
deprivation has been implicated in the elimination of the majority of these clonally expanded T 
cells (22, 23). T-cell receptor (TCR) cross-linking leads to activation of resting T cells, whereas 
it induces apoptosis (activation-induced cell death [AICD]) in activated T cells (24). AICD has 
also been implicated in apoptosis during thymocyte development (25) and in the depletion of 
autoreactive T cells (24, 26). Furthermore, growth factor deprivation-induced apoptosis is 
independent of Fas-mediated signaling pathways, because patients with autoimmune 
lymphoproliferative syndrome have AICD defects (27, 28) despite normal growth factor 
deprivation-induced apoptosis (29). 
 
The fate of cytoplasmic mRNAs was analyzed after triggering of apoptosis by direct cross-
linking of the death receptor CD95, AICD, or growth factor deprivation. These experiments 
demonstrated that mRNA degradation is a general early apoptotic event taking place in all the 
analyzed cell lines, and also during in vivo physiological situations. Apoptosis-induced mRNA 
degradation is independent of the stimulus used, precedes DNA fragmentation, and is an active 
process that can be dissected from DNA fragmentation, PARP processing, and annexin V 
binding by the use of caspase inhibitors. These data suggest that a distinct signaling pathway, 
induced by death receptor triggering, is responsible for mRNA degradation during apoptosis. 
 
MATERIALS AND METHODS 
 
Cell lines, culture conditions, and reagents 
 
A20 (ATCC No. TIB208) is a mature murine (BALB/c) B cell line (30) (provided by Dr. Brás). 
CTLL-2 (ATCC No. TIB214) is a mouse cytotoxic T-cell clone requiring exogenous interleukin 
2 (IL-2) for growth (31) (a gift from Dr. Erard). J-HM1-2.2 cells (hereafter referred to as 
JHM12) is a Jurkat derivative constitutively expressing the human muscarinic type I receptor 
(HM1R) (32) (provided by Dr. Weiss). JHM12-p35 was derived from JHM12 cells after the 
cDNA coding for the Autographa californica p35 gene was stably transfected under the control 
of the EF1α promoter. Transfectants were selected by five rounds of treatment with anti-CD95 
monoclonal antibody (mAb) (50 ng/ml, 48 h). Molt-4 (ATCC No. CRL-1582) is a human acute 
lymphoblastic leukemia cell line, which undergoes apoptosis after treatment with 316 nM 
okadaic acid (33). All cells were cultured in IMDM-10 (Iscoves modified Dulbeccos medium 
containing 10% heat-inactivated FCS, 10 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic 
acid [HEPES] pH 7.0, 0.05 mM β-mercaptoethanol, and 2 mM glutamine). CTLL-2 cells were 
supplemented with saturating concentrations of mouse rIL-2 (34). 
 
AICD was induced in JHM12 cells (106 cells/ml) by activation with 500 µM carbachol (Sigma, 
St. Louis, MO) (35) or plate-coated 10 µg/ml anti-CD3ε mAb (T3b). For direct CD95 triggering 
of A20 or JHM12, these cells were treated with 50 ng/ml Jo2 mAb (PharMingen, San Diego, 
CA) or CH-11 mAb (Upstate Biotechnology, Lake Placid, NY), respectively. For mRNA half-
life measurements, JHM12 cells were treated with carbachol (500 µM, 1 h) before addition of 5 
µM actinomycin D; this concentration of actinomycin D inhibits more than 90% of [3H]UTP 
incorporation into trichloroacetic acid precipitable counts (not shown). Apoptosis caused by 
growth factor deprivation was induced in exponentially growing CTLL-2 cells after cells were 
washed three times in fresh IMDM-10 medium and were then resuspended at 0.5 × 106 cells/ml 
in fresh IMDM-10 devoid of IL-2. The irreversible and cell-permeable caspase inhibitor Z-
VAD-fmk (Z-Val-Ala-Dl-Asp fluoromethylketone; No. N1510; Bachem, Bubendorf, 
Switzerland) was added at a final concentration of 100 µM at the specified times. 
 
Antigen-induced thymocyte apoptosis 
 
T-cell receptor Vα4Vβ11 double transgenic mice (F5-TCR, provided by Dr. Kioussis) recognize 
the influenza virus A nucleoprotein peptide (NP-366-374) in the H2-Db context (36). 
Intraperitoneal injection of antigenic peptide NH2-ASNENMDAM-COOH (Isogen, Maarssen, 
The Netherlands) in 200 µl of PBS (9-75 nmol) leads to antigen-induced apoptosis of immature 
thymocytes (CD4+CD8+ cells are affected). Ninety minutes after injection, animals were killed 
by cervical dislocation, single thymocyte cell suspensions were obtained and minced through a 
150-µm nylon mesh, and aliquots were used for analysis of 1) thymocyte subpopulations after 
staining with CD4 and CD8 mAb (1 × 106 cells), 2) genomic DNA fragmentation (20 × 106 
cells), 3) PARP processing (5 × 106 cells), and 4) RNA preparation of thymocytes (20 × 106 
cells) alone or mixed with 5 × 106 JHM12 cells. 
 
Cytofluorometric analysis 
 
After induction of apoptosis, annexin V binding to phosphatidylserine exposed on the outer 
surface of the membrane was measured by flow cytometry with fluorescein isothiocyanate 
(FITC)-labeled annexin V (Immunotech, Marseille, France). For cell cycle analysis, cells were 
permeabilized, were stained with propidium iodide (DNA-Prep Reagents Kit, Beckman Coulter, 
Miami, FL), and, after RNA digestion (30 min, 37°C), were analyzed by flow cytometry to 
determine the fraction of surviving cells (G0/G1, S, and M phases of the cell cycle) and nonviable 
cells (sub-G0/G1 phase). Cell suspensions from the thymus were stained with saturating 
concentrations of anti-CD4-FITC mAb and anti-CD8-phyco mAb (PharMingen) and were 
evaluated by multiparameter analysis. 
 
Western blot analysis 
 
Cytosolic cell extracts were prepared by incubation (30 min, 4°C) in extraction buffer (50 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 0.5 mM EDTA, 1% Nonidet-P40, 1 mM phenylmethylsulfonyl 
fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 µg/ml pepstatin), followed by high-speed 
centrifugation of lysates. Cytosolic extracts (30 µg/lane) were resolved by 8% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-
Rad, Hercules, CA). Western blots were performed with an anti-human PARP mAb, which 
recognizes mouse and human PARP (Labgen, Oxford, UK; 1:750 dilution), followed by 
horseradish peroxidase-conjugated anti-mouse IgG (Dako, Glostrup, Denmark), and blots were 
developed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Uppsala, Sweden). 
 
RNA preparation and analysis 
 
Cytoplasmic RNA was prepared by using the NP40 method (37); thymocyte total RNA was 
prepared by the guanidinium-thiocyanate-acid phenol method (37). After electrophoresis through 
denaturing 1.2% formaldehyde-agarose gels, RNA samples were transferred to nylon membranes 
(GeneScreen, New England Nuclear, Boston, MA), and rRNA distribution was visualized by 
methylene blue staining (38). Northern blots were hybridized sequentially with specific cDNA 
probes labeled either with [α32P]dCTP by using the random priming method or with [α32P]CTP-
labeled cRNA probes (39). For 28S rRNA analysis, an oligonucleotide complementary to 
nucleotides 4205-4225 (provided by Dr. E. W. Müllner) was end-labeled with [γ-32P]ATP using 
poly-nucleotide kinase. After samples were washed, filters were exposed and quantified by 
phosphorimaging (Molecular Dynamics, Sunnyvale, CA). The background from each sample 
was subtracted by using the local median algorithm of the program ImageQuant (v.1.2, 
Molecular Dynamics). 
 
DNA fragmentation assays 
 
Analysis of DNA fragmentation was carried out as described previously (40), followed by 
incubation with 10 µg of RNase A (30 min, 37°C), subsequent electrophoresis in 2% agarose 
gels, visualization by ethidium bromide staining, and photography after UV light exposure. 
RESULTS 
 
CD95-induced apoptosis triggers degradation of cytoplasmic mRNAs 
 
Direct CD95 cross-linking with its specific ligand (Fas-L) or with agonistic mAb induces 
apoptosis in activated T cells and T-cell lymphomas (41). In Jurkat cells treated with 50 ng/ml 
anti-CD95 mAb, onset of apoptosis can be ascertained by 1) appearance of phosphatidylserine in 
the outer cell membrane, as measured by annexin V binding; 2) processing of the caspase 
substrate PARP; and 3) degradation of nuclear DNA, quantified by an increase in the fraction of 
cells in the sub-G0/G1 cell cycle phase. As early as 1 h after apoptotic insult, there was a 
significant increase in the amount of processed PARP and detectable annexin V binding, both of 
which increased over time. At 5 h after CD95 triggering, 62% of cells were positive for annexin 
V and the vast majority of PARP had been processed (Fig. 1A). These changes were followed by 
an increase in the fraction of cells in the sub-G0/G1 cell cycle phase (Fig. 1A). Thus, this model 
functions as a suitable tool for analysis of the fate of cellular mRNA during apoptosis. 
 
The analysis of the mRNAs coding for the T-cell receptor β chain (TCRβ), major 
histocompatibility complex (MHC) class I α-chain (HLA-I), and β-actin revealed a substantial 
decrease in expression levels of all these mRNAs after induction of apoptosis (Fig. 1B) because 
of mRNA degradation (see below). mRNA degradation kinetics paralleled the appearance of 
annexin V-positive cells and preceded nuclear DNA fragmentation (Fig. 1C). In addition, the 
methylene blue staining pattern of RNA samples indicated degradation of 28S rRNA (Fig. 1B, 
open arrowheads). Specificity of apoptotis-induced mRNA degradation was demonstrated by 
processing Jurkat cells alone (−A20) or mixed, before lysis and RNA preparation, with A20 
mouse control cells (+A20), followed by Northern hybridization with human- and mouse-
specific probes. Similar degradation kinetics were observed for human mRNAs when samples of 
Jurkat cells were processed either alone (−A20) or mixed with nonapoptotic control cells 
(+A20), whereas mouse-specific IAα mRNA levels remained unchanged in samples containing 
control cells (+A20) and were undetectable in samples devoid of control cells (−A20). Taken 
together, these data indicate that CD95 triggering induces specific mRNA degradation, as part of 
the early apoptotic response, in Jurkat cells. 
 
The Jurkat cell model also allowed analysis of mRNA degradation during AICD, one of the 
major mechanisms controlling immune system homeostasis (1). The fate of genes expressed in a 
constitutive (TCRβ, HLA-I, and β-actin) or inducible (early activation marker CD69) fashion, as 
well as 28S rRNA, was analyzed in JHM12 cells after carbachol treatment, which induces AICD 
in these cells (35). In agreement with the findings for CD95-induced apoptosis, all mRNAs 
analyzed after AICD were rapidly degraded, which correlated with the appearance of annexin V 
binding (Fig. 2). The similar degradation kinetics of Jurkat mRNAs in the presence (+A20) or 
absence (−A20) of control cells, whereas the A20-specific mRNA (IAα) remained intact (Fig. 2), 
again indicated specificity of the apoptosis-induced mRNA degradation. The apparent difference 
in β-actin degradation kinetics between samples containing Jurkat mRNAs alone or mixed with 
A20 can be explained by the cross-reactivity of this probe between mouse and human samples 
(Fig. 2). The 28S rRNA probe also cross-reacts with mouse and human samples, but degradation 
of this rRNA could be quantified by appearance of specific degradation products (a 20-fold 
increase in the 28S rRNA degradation product was concomitant with a 5- to 33-fold degradation 
of the mRNAs 8 h after apoptosis triggering) (Fig. 2A), which showed similar kinetics in the 
presence or absence of control A20 cells (Fig. 2B, inset). 
 
 These data show that after apoptosis induction in Jurkat cells, by either direct CD95 cross-
linking or AICD, cytoplasmic mRNA degradation is an early event, concomitant with the 
appearance of annexin V-positive cells (Figs. 1 and 2). This degradation affects all mRNAs 
analyzed, independently of the transcriptional status of the gene, as well as 28S rRNA.  
 
To demonstrate that the apoptosis-induced decline in mRNA hybridization signals was indeed 
due to an active degradation rather than to an apoptosis-induced transcriptional arrest, mRNAs 
half-lives in nonapoptotic cells were analyzed and shown to be different from the apoptosis-
induced degradation kinetics. Cells were preactivated with carbachol (1 h) before transcription 
was blocked with actinomycin D, to allow mRNA half-life analysis of activation-inducible 
(CD69) transcripts and of constitutive mRNAs. This short activation is not sufficient to trigger 
apoptosis because, during the course of the experiment, there was no significant increase in the 
fraction of annexin V-positive cells and PARP processing was detected only at longer times (>3 
h, even in the absence of transcription inhibitors, not shown). In JHM12 cells, CD69 mRNA had 
a short half-life (about 20 min), as previously reported (42), whereas the other mRNAs did not 
decay significantly during the course of the experiment (Fig. 3). Actinomycin D treatment, 
although restricted to 4 h because of toxicity at longer treatment times, allowed us to estimate 
that HLA-I, β-actin, and TCRβ mRNA half-lives were longer than 10 h, in accordance with 
published data (43, 44). Thus, mRNAs with different half-lives showed similar apoptosis-
induced degradation kinetics, indicating that apoptosis-induced mRNA degradation is an active 
process. 
 
Apoptosis-induced mRNA degradation was a general event independent of cell type and 
apoptosis triggering pathway 
 
To exclude the possibility that apoptosis-induced mRNA degradation was restricted to the 
JHM12 Jurkat T-cell clone, apoptosis was induced in mouse A20 cells (used as control in the 
above experiments) by direct CD95 cross-linking with mAb. A20 mRNAs (IAα, BAX) were 
degraded during CD95-induced apoptosis, whereas HLA-I mRNA from mixed control Jurkat 
cells remained intact (Fig. 4), which again demonstrated the specificity of the apoptosis-induced 
mRNA degradation. The kinetics of apoptosis-induced mRNA degradation also correlated with 
increased annexin V binding. These data demonstrated that apoptosis-induced mRNA 
degradation was not restricted by cell line and strengthened the idea that it is an early general 
mechanism affecting different mRNAs, including those encoding proteins implicated in cell 
death, such as the proapoptotic protein BAX (45, 46). 
 
In addition to AICD, growth factor deprivation is the other major mechanism that induces T-cell 
apoptosis and allows maintenance of T-cell homeostasis after clonal expansion. The IL-2-
dependent murine cytotoxic T lymphocyte cell line CTLL-2 was used as a model for growth 
factor deprivation-induced apoptosis. In these cells, IL-2 withdrawal induced an increase in the 
sub-G0/G1 cell fraction, which indicated DNA degradation (Fig. 5A). It is noteworthy that in 
comparison to CD95 cross-linking and AICD, the appearance of annexin V-positive cells was 
delayed, rather than preceding DNA fragmentation, and had kinetics similar to the kinetics of 
DNA fragmentation (Fig. 5B). 28S rRNA degradation and appearance of the characteristic 
intermediates were detectable within 12 h after growth factor withdrawal (Fig. 5A). β-Actin 
mRNA, as an example of cytoplasmic transcript, was also degraded as an early event detectable 
after 12 h, in fact preceding both the appearance of annexin V binding and DNA fragmentation 
(Fig. 5B). 
 
Distinct pathways lead to mRNA degradation and other apoptotic hallmarks after CD95 
cross-linking 
 
Because CD95-induced apoptosis is inhibited by the general caspase inhibitor Z-VAD-fmk, its 
effect on apoptosis-induced mRNA degradation was analyzed. As expected, pretreatment with 
100 µM Z-VAD-fmk inhibited the increases in annexin V binding, cells in the sub-G0/G1 phase 
of the cell cycle, and PARP processing, which were induced by 5 h anti-CD95 mAb, as well as 
cytoplasmic mRNA degradation, in both A20 and Jurkat cells (Fig. 6). 
 
When apoptosis was induced in A20 cells for 6 h with anti-CD95, and the caspase inhibitor Z-
VAD-fmk was added at different times, conditions could be defined in which all described 
apoptotic events, except for mRNA degradation, were abrogated. Indeed, whereas Z-VAD-fmk 
addition either 1 h before or at the same time as anti-CD95 led to complete inhibition of all 
apoptotic markers including mRNA degradation, its addition 0.5 h after anti-CD95 mAb 
revealed degradation of more than 50% of the mRNA, with no detectable PARP processing and 
only background levels of DNA degradation or annexin V binding (Fig. 7). When Z-VAD-fmk 
was added at later times after CD95 triggering, a similar fraction of mRNA was degraded, 
concomitant with a progressive increase in PARP processing, annexin V-positive cells, and cells 
in the sub-G0/G1 phase of the cell cycle (Fig. 7). Similar results were obtained with JHM12 cells 
(not shown). Thus, these data allowed us to conclude that apoptosis-induced mRNA degradation 
can occur in the absence of other apoptotic markers. Z-VAD-fmk inhibition kinetics also showed 
striking differences between mRNA degradation and annexin V binding, DNA degradation, and 
PARP degradation, the last three being progressively abrogated. This result indicates that anti-
CD95 mAb triggers different downstream signaling pathways, one responsible for annexin V 
binding, DNA fragmentation, and PARP processing, and the other implicated in mRNA 
degradation. 
 
In addition, mRNA degradation was analyzed in JHM12-p35 cells, in which anti-CD95 mAb-
induced apoptosis was completely blocked by constitutive expression of the baculoviral caspase 
inhibitor p35. Indeed, p35 expression abrogated DNA fragmentation and inhibited appearance of 
annexin V-positive cells. Most interesting, although the cells kept proliferating at the same rate, 
a substantial fraction of mRNA was still degraded (Fig. 8). These data further substantiate the 
notion of a distinct downstream signaling pathway responsible for mRNA degradation during 
apoptosis. 
 
Taken together, these data show that apoptosis induces, as an early event, degradation of 
mRNAs with different intrinsic half-lives by an active process, as demonstrated by transcription-
blocking experiments. The pathways can be dissected from the one leading to the other apoptotic 
hallmarks. These data also demonstrate that although apoptosis-induced mRNA degradation is 
not restricted by cell line or stimuli, it is not sufficient to induce cell death. 
 
Apoptosis-induced mRNA degradation occurs in vivo as an early apoptotic event 
 
To determine whether apoptosis-induced mRNA degradation was a general apoptosis marker 
rather than restricted to cell lines, we extended the analysis to an in vivo apoptosis model. In the 
thymus, TCR triggering leads to immature thymocyte elimination (negative selection). This 
process can be mimicked in F5-TCR mice by the injection of the antigen specifically recognized 
by the TCR, which leads to massive apoptosis of immature thymocytes (CD4+CD8+).  
Interestingly, PARP processing and DNA fragmentation could be detected in treated mouse 
thymocytes as early as 90 min after peptide injection, when no reduction in cell numbers had yet 
taken place, but not in thymocytes from control animals (PBS injected) (Fig. 9A, B).  
 
Thymocyte RNA was prepared either alone  (−JHM12) or mixed with human control cells 
(+JHM12). Specific degradation of the two CD8α mRNA species was demonstrated, without 
significant degradation of control human mRNA (TCRβ) in the mixture (Fig. 9 C, D). In this in 
vivo model, mRNA degradation also affected a fraction of the transcripts higher than the 
corresponding fraction of cells with fragmented DNA (cells in the sub-G0/G1 phase of the cell 
cycle) (Fig. 9D). 
 
DISCUSSION 
 
The data presented here demonstrate that mRNA degradation is a general early apoptosis-
induced event and that it can be dissected from other processes that occur during programmed 
cell death. The hallmarks of apoptosis are 1) chromosomal DNA fragmentation into mono- and 
polynucleosomes, detectable as a DNA ladder (8); 2) caspase activation (47, 48), which leads to 
cleavage of specific protein substrates (10, 11, 16, 48, 49), and 3) phosphatidylserine exposure at 
the cell surface, detectable as annexin V binding (50). Recent data showed that apoptosis induces 
a broad spectrum of changes in cellular proteins (12). In addition, apoptosis-induced degradation 
of 28S rRNA (18, 51, 52), mitochondrial 16S rRNA (53), and the Ro ribonucleoprotein-
associated Y RNAs (19) has been reported, although so far nothing was known about the fate of 
cytoplasmic mRNAs. 
 
The data reported here demonstrate degradation of cytoplasmic mRNAs during apoptosis. 
Specificity was shown by mixing experiments in which mRNAs derived from apoptotic cells 
were degraded, whereas control cell mRNAs remained intact. Apoptosis-induced mRNA 
degradation is not restricted to genes with a specific function, because besides 28S rRNA, the 
mRNAs analyzed encode proteins implicated in cell type-specific functions, proteins such as 
HLA-I, IAα, TCRβ, and CD69; structural proteins such as β-actin; and proteins involved in the 
control of cell survival, such as BAX. 
 
Apoptosis-induced specific RNA degradation is neither cell line nor species restricted, because it 
was observed in nontransformed mouse T-cell lines (CTLL-2) (Fig. 5), mouse B-cell lymphomas 
(A20) (Figs. 4, 6, and 7), human T-cell leukemias (Jurkat) (Figs. 1, 2, 6, and 8), and T-cell 
lymphomas (Molt-4) (not shown), as well as in mouse  thymocytes in vivo (Fig. 9). 
 
Furthermore, mRNA degradation, rather than being restricted to an apoptosis signaling pathway, 
was observed after triggering through Fas-mediated signaling pathways (CD95 cross-linking or 
AICD) (Figs. 1, 2, and 4) (41, 54, 55), as well as by stimuli such as growth factor deprivation 
(Fig. 5) and okadaic acid treatment (data not shown), both independent of Fas (29, 56-58). 
 
Taken together, these data indicate that apoptosis-induced mRNA degradation is not restricted 
by stimulus, cell line, or species and that it affects all mRNAs analyzed, which suggests that 
mRNA degradation is, at least in lymphocytes, a general feature of the cell death program. 
Indeed, in this report we demonstrate that mRNA degradation occurs upon apoptosis triggering 
by stimuli not requiring de novo transcription or translation, such as direct Fas triggering (Figs. 
1, 4, 6, 7, and 8), and also upon AICD and growth factor deprivation (Figs. 2 and 5), both of 
which do require transcription and translation. 
 
Kinetics studies showed that after Fas triggering or AICD, mRNA degradation precedes DNA 
degradation and correlates with the appearance of the early apoptotic marker annexin V (Figs. 1, 
2, and 4). When apoptosis is induced by growth factor deprivation, however, the appearance of 
annexin V-positive cells and DNA fragmentation, which are preceded by mRNA degradation, 
have similar kinetics (Fig. 5). This result indicates that apoptosis-induced specific mRNA 
degradation is an early event and not simply the consequence of the metabolic collapse of the 
cell. 
 
mRNA degradation is an active process rather than the consequence of an apoptosis-induced 
transcriptional blockade. Indeed, the intrinsic half-life of CD69 mRNA was very short (about 20 
min, Fig. 3), and apoptosis induced an apparent stabilization, as demonstrated by the slower 
decay of the mRNA (about 1.5 h, Fig. 2). Conversely, for other mRNAs (HLA-I, β-actin, and 
TCRβ) with intrinsic long half-lives (>10 h, Fig. 3), apoptosis-induced degradation led to an 
increased turnover (about 2-3 h, Fig. 2). Apoptosis-induced degradation kinetics for all mRNAs 
analyzed were very similar (β-actin, TCRβ, HLA-I, IAα, CD69, and BAX) (Figs. 1, 2, and 4) 
and obviously independent of the intrinsic half-lives of the mRNAs in the cell. 
 
Unlike β-actin, TCRβ, or HLA-I transcripts, CD69 mRNA contains AU-rich elements (ARE) in 
its 3'-untranslated region (42), which destabilize otherwise stable mRNAs (59). Tight control of 
ARE-containing transcript stability occurs through interaction of these cis-regulatory elements 
with specific binding proteins involved in mRNA turnover (60). Apoptosis-induced CD69 
mRNA decay has different, slower kinetics than its estimated half-life, which indicates that a 
mechanism different from ARE-mediated decay is implicated in apoptosis-induced degradation. 
Non-ARE-containing mRNAs are also degraded during apoptosis, although with faster kinetics 
than their corresponding half-lives, indicating that a specific mechanism is responsible for 
mRNA degradation triggered by apoptosis. This further substantiates the idea that mRNA 
degradation is a generalized feature of the apoptotic program. 
 
In addition, the general caspase inhibitor Z-VAD-fmk (61) inhibited expression of all apoptotic 
markers including mRNA degradation (Fig. 6), whereas the more restricted caspase inhibitor 
p35, which completely blocks CD95-induced apoptosis, was unable to fully abrogate mRNA 
degradation (Fig. 8). The molecular mechanisms implicated in apoptosis-induced mRNA 
degradation are unknown. Nonetheless, it could be speculated that mRNA degradation depends 
on an upstream apical caspase (inhibited by Z-VAD-fmk but not p35) unable to cleave PARP. 
Conversely, it might be envisaged that in addition to caspases, Z-VAD-fmk inhibits other 
molecules (not inhibited by p35), including those responsible for RNase activation.  
 
Kinetic analysis with caspase inhibitors not only allowed delineation of conditions in which 
mRNA degradation occurs in the absence of annexin V binding or DNA or PARP degradation 
but also demonstrated that the mechanisms involved in mRNA degradation were fully active as 
early as 0.5 h after Fas cross-linking, whereas inhibition of other apoptotic hallmarks was 
progressively abrogated (Fig. 7). These findings strongly suggest that the signaling pathways 
induced by anti-Fas mAb can be kinetically dissociated into one route leading to mRNA 
degradation and another one leading to PARP processing, annexin V binding, and DNA 
fragmentation. The baculoviral p35 experiments (Fig. 8) corroborated the notion that a distinct 
signaling pathway is responsible for mRNA degradation during apoptosis. Furthermore, 
extensive mRNA degradation, although apparently a general early apoptotic event, is not 
sufficient to induce cell death per se. 
 
During maturation, thymocytes are subject to positive and negative selection processes, in which 
the large majority of cells die by apoptosis; only about 5% of cells successfully complete 
maturation. The negative selection process has been mimicked in vivo in TCR transgenic mice 
by antigen injection, which leads to the elimination of the vast majority of CD4+CD8+ 
thymocytes (36, 40). Specific mRNA degradation in these cells was demonstrated as early as 90 
min after antigen injection, preceding DNA degradation. This finding was thus a clear indication 
that apoptosis-induced mRNA degradation is a general early event that occurs not only in T-cell 
lines but also in vivo. 
 
These observations raise a question about the nature of the RNases involved, which remains to 
be elucidated. By analogy to the CAD, which after cleavage of its specific inhibitor ICAD is 
activated and translocates to the nucleus (16), a similar model can be envisaged for a caspase-
activated RNase. CAD itself cannot be responsible for degradation of mRNA because 1) under 
conditions in which CAD was inhibited, there was still 28S rRNA degradation (18, 33), 2) 
kinetic analysis with caspase inhibitors allowed differentiation of conditions in which mRNA 
degradation occurs in the absence of DNA degradation (Fig. 7), 3) similar results were obtained 
in Jurkat cells constitutively expressing the caspase inhibitor p35 (Fig. 8), and 4) the presence in 
Jurkat cells of DEVD (a caspase-3 inhibitor) prevented DNA fragmentation induced by anti-
CD95 mAb, whereas the mRNA was still degraded (not shown). 
 
Detailed molecular analysis of apoptosis-induced 28S rRNA degradation products suggests that 
RNase L may be the RNase involved (51, 62). RNase L is found in nearly all mammalian cell 
types and tissues (63) and was initially described as an interferon-inducible enzyme (63). RNase 
L−/− mice show defective apoptosis in the thymus and spleen; in vitro thymocyte- and fibroblast-
induced apoptosis is also defective (62). These findings, together with the similar decay kinetics 
of 28S rRNA and mRNAs, allow us to hypothesize that RNase L may be one of the enzymes 
implicated in apoptosis-induced mRNA degradation. RNase L cleavage of 28S rRNA gives a 
defined pattern of readily detectable degradation intermediates (51, 62), similar to the pattern 
observed in the experiments presented here (Figs. 1, 2, and 4-7). For cytoplasmic mRNAs, 
however, degradation intermediates remained elusive so far (Figs. 1, 2, and 4-7), which may be 
due to the high degradation rate and the intrinsic difficulty of detecting degradation 
intermediates from transcripts of low or intermediate abundance or conversely may be 
interpreted as the involvement of different RNases in the degradation of cytoplasmic mRNAs. 
Further experiments are needed to identify RNase activities responsible for degradation of the 
bulk of cytoplasmic mRNAs. 
 
Thus, apoptosis induces degradation of the cytoplasmic mRNAs but also degradation of 28S 
rRNA and cleavage of translation initiation factors (eIF4GI, eIF4GII) (64, 65), which suggests 
that the cell, by different means, blocks protein synthesis, which may be a prerequisite for 
reaching the point of no return in the cell death program. Furthermore, degradation of cellular 
mRNA is a general early apoptotic event, which may be considered a hallmark of apoptosis. This 
finding has clear implications in the field of mRNA turnover, as well as for the physiology of 
apoptosis, because it demonstrates for the first time a generalized change in mRNA stablility 
induced by an external stimuli and, in addition, will have to be taken into account in experiments 
aimed at identifying genes involved in the cell death process. 
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Fig. 1 
 
 
 
Figure 1. Direct triggering of death receptors induced specific mRNA degradation. Representative 
experiment showing the kinetics of annexin V binding, DNA degradation, PARP processing, and mRNA 
degradation after Fas triggering. A) The kinetics of apoptosis induction after anti-Fas treatment was quantified 
as the fraction of cells positive for annexin V, cells in the sub-G0/G1 phase of the cell cycle, and kinetics of 
PARP processing (115 kDa, unprocessed form; 85 kDa, processed form) (empty boxes indicate that the analysis 
at that time point was not determined). B) Northern blots of RNA from human JHM12 cells alone (−A20, left 
panels) or in combination with mouse control cells (+A20, right panels), showing methylene blue staining of 
filters (top) and hybridization with specific JHM12 mRNAs (T-cell receptor β chain [TCR β], HLA class I 
[HLA-I]), as well as hybridization with a probe specific for the mouse A20 control cells (MHC class II mRNA 
[Iaα]). C) Quantification of data from A and B, represented for comparison purposes as 100 minus the 
percentage of annexin V-positive cells, or 100 minus the percentage of cells in the sub-G0/G1 phase of the cell 
cycle, and percentage of remaining mRNA for Northern blots, after correction of the specific signal for each 
transcript with the values obtained for the control IAα mRNA. 
 
Fig. 2 
 
 
 
Figure 2. Apoptosis-induced cell death triggered mRNA degradation. After induction of AICD by  
carbachol in Jurkat JHM12 cells, the kinetics of cytoplasmic mRNA degradation were analyzed.  A) 
Methylene blue staining of cytoplasmic RNA from Jurkat cells alone (−A20) or in combination with control 
cells (+A20) (staining, top panel). Relative expression levels are shown for 28S rRNA, TCRβ, HLA-I, β-actin, 
and CD69 in Jurkat cells, as well as for the A20 cell-specific IAα mRNA. Open arrowheads indicate 28S rRNA 
degradation products. B) Quantification of data in A, represented for all transcripts, including the control IAα 
mRNA, as a percentage of the remaining mRNA and the fraction of cells positive for annexin V, which for 
comparative purposes is represented as 100 minus the percentage of annexin V. The inset in B represents the 
appearance kinetics of the 28S rRNA degradation product (open arrowhead in the 28S rRNA panel in A). 
Fig. 3 
 
 
 
Figure 3. Analysis of mRNA turnover in Jurkat cells. After 1 h of carbachol activation of JHM12 cells and 
subsequent de novo transcription blockade with 5 µM actinomycin D, turnover of CD69, TCRß, HLA-I, and ß-actin
mRNA was analyzed. Cells were harvested at different times (0-4 h) and cytoplasmic RNAs were prepared. A) 
Northern hybridization with specific cDNA probes. B) Quantification of hybridization data from A. 
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Figure 4. Apoptosis-induced mRNA degradation is not restricted by cell type. Analysis of CD95-induced mRNA  
degradation in mouse A20 cells. A) Northern blot showing degradation of A20 mRNAs (IAα and BAX), whereas 
mRNA from control JHM12 cells (HLA-I) remained intact. B) Quantification of data in A, represented for all transcripts, 
including the control HLA-I mRNA, as percentage of the remaining mRNA, together with the fraction of cells positive for 
annexin V, which for comparative purposes is represented as 100 minus the percentage of annexin V. 
 
Fig. 5 
 
 
 
Figure 5. mRNA degradation after apoptosis induced by growth factor deprivation. Exponentially growing CTLL-2 
cells were deprived of growth factor and cultured for different time periods (0-22 h) in the absence of IL-2. After cells 
were harvested, aliquots of cells were used to quantify the percentage of dead cells (annexin V staining and DNA 
degradation), as well as to prepare cytoplasmic RNA. A) Propidium iodine staining of permeabilized cells to determine 
the DNA profiles. Time-dependent degradation of β-actin mRNA and 28S rRNA, concomitant with the appearance of 28S 
degradation products. B) Quantification of β-actin mRNA degradation kinetics, appearance of cells in the sub-G0/G1 phase 
of the cell cycle, and annexin V-positive cells. 
 
Fig. 6 
 
 
Figure 6. Apoptosis-induced mRNA degradation was inhibited by a general caspase inhibitor. Triggering of CD95 
with specific mAbs induced apoptosis and specific mRNA degradation in both A20 (A, B) and JHM12 (C, D) cells. 
Treatment of cells with 100 µM Z-VAD-fmk, before CD95 triggering for 5 h, inhibited the appearance of the apoptotic 
markers DNA fragmentation, PARP processing, and annexin V-positive cells (B, D) and abrogated cytoplasmic mRNA 
degradation in both cell lines. In A, A20 cells treated with Fas were mixed with JHM12 control cells, whereas in C the 
JHM12 cells were treated with Fas and mixed with A20 control cells. The quantified mRNA signals shown in B and D are 
represented as the percentage of remaining mRNA after correction for the signal obtained with the mRNAs from the 
control cells. The inhibition of mRNA degradation by Z-VAD-fmk in JHM12 cells is not complete (C, D), because of the 
variability between experiments (in other experiments, full inhibition had been observed). 
Fig. 7 
 
 
Figure 7. Kinetics of Z-VAD-fmk inhibition of apoptosis in A20 cells allowed discrimination between 
mRNA degradation and other apoptotic markers. The kinetic effects of Z-VAD-fmk were analyzed with 
A20 cells treated for 6 h with anti-Fas mAb, when the inhibitor was added at different times ranging from 1 h 
before to 1.5 h after the addition of anti-Fas antibody. Control, untreated cells had the following characteristics: 
3% were annexin V positive, 1% were in the sub-G0/G1 phase of the cell cycle, and PARP processing was 
undetectable; anti-Fas-treated cells had the following characteristics: 73% were annexin V positive, 59% were 
in the sub-G0/G1 phase, the vast majority of PARP was processed; and 84% of mRNA was degraded. A) 
Methylene blue staining of the RNA samples, hybridization with the specific murine IAα mRNA, and detection 
of PARP processing by Western blotting. B) Quantification of annexin V-positive cells, cells in the sub-G0/G1 
phase, and IAα mRNA degradation. 
 
Fig. 8 
 
 
 
Figure 8. p35 inhibited apoptosis but did not abrogate mRNA degradation. Experiments such as those described in 
the legend to Fig. 6 were carried out with Jurkat JHM12 cells or Jurkat cells constitutively expressing p35, a caspase 
inhibitor that abrogates apoptosis induced by direct triggering of death receptors. A) mRNA expression levels in wild-type 
and p35-expressing cells, before and after an 8-h treatment with anti-CD95 antibodies. Fas-treated cells were mixed with 
A20 control cells to demonstrate specificity of the degradation. B) Quantification of data shown in A, represented as a 
percentage of the remaining mRNA after correction of the specific HLA-I signal for each lane with the values obtained for 
the control IAα mRNA. 
 
Fig. 9 
 
 
 
Figure 9. mRNA degradation was found to be an early step in in vivo  antigen-induced thymocyte apoptosis. 
Representative experiment demonstrating that thymocyte apoptosis was induced by intraperitoneal injection of antigenic 
peptide (9-75 nmol) in F5-TCR transgenic mice; injection of PBS served as the control. Samples were analyzed 90 min 
after injection; one animal was used for each peptide concentration. A) PARP processing. B) DNA fragmentation. C) 
mRNA expression levels for mouse CD8α and control human TCRβ in samples of thymocytes alone (−JHM12) or mixed 
with JHM12 cells (+JHM12). D) Quantification of the fraction of cells in the sub-G0/G1 phase of the cell cycle, together 
with the data from C, represented as a percentage of remaining mRNA after correction, for each lane, of the specific 
CD8α signals with the values obtained for the control TCRβ mRNA. 
